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EVALUATING SYSTEMATIC REVIEWS AND METAANALYSES
Lisa A. Bero, Ph.D.*
If one’s first impression of the world’s clinical literature
is that of its fearsome immensity; one’s second is likely to
be that of its appallingly poor average quality. The two are
obviously interconnected; the drug literature is
overburdened by a vast volume of superfluous and even
dangerous rubbish. The standards of medical journals range
from the sublime (of which there are very few) to the
disgraceful.
Graham Dukes, MD MA LLM, 19771
INTRODUCTION
Information overload in the medical field is not a new problem.
In fact, it just gets worse as more information of questionable
validity accumulates. As much of this information appears as
“scientific evidence” in the courtroom, there is a pressing need for
law professionals to understand state-of-the-art methods for
*

Professor in the Department of Clinical Pharmacy at the Institute for
Health Policy Studies, University of California, San Francisco. Dr. Bero thanks
Nick Royle, CEO, Cochrane Collaboration for assistance with preparing figure
2.
1
Dr. Graham Dukes is currently with the Unit for Drug Policy Studies,
University of Oslo. Having held senior positions with national regulatory
authorities, World Health Organization (WHO), and World Bank (WB), he has a
distinguished professional record. Graham Dukes has peerless experience in the
areas of drug policy, legislation, regulation, utilization studies, information
services, adverse reaction monitoring, medical risk management and
professional training. He has assisted numerous countries in the development of
new polices, reorganization of regulatory systems, the design of new
pharmaceutical legislation and supply structures.
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critically appraising and summarizing massive amounts of
scientific data.
Systematic reviews and meta-analyses are powerful methods
for gathering, critiquing and summarizing medical and scientific
information. Systematic reviews are combinations of results that
adhere to pre-defined methods, but that may not result in
quantitative combination of the data. Meta-analysis is a
quantitative approach to systematically combining the results of
previous studies. A meta-analysis that does not start as a
systematic review may be published, but, for reasons described
below, it would not be a high quality review.
The use of meta-analyses and systematic reviews to guide
clinical practice is increasing.2 Systematic reviews and metaanalyses of randomized controlled trials are the most
methodologically rigorous forms of evidence to evaluate the
effectiveness
of
therapeutic
interventions,
particularly
pharmacotherapy.3 They often form the foundation for practice
guidelines, clinical decision support systems, drug formulary
decisions, and drug payment schemes.
Healthcare practitioners, researchers, and anyone interested in
answering scientific or medical questions would like to be able to
turn to the ideal report of research findings. This ideal report
would, in one place, summarize data from all studies available on a
particular topic. The studies would be critically evaluated using
unbiased methods. The report would be instantly accessible and
kept up to date as new data accumulated.
The Cochrane Collaboration, whose logo is illustrated in
Figure 1,4 aspires to provide this ideal source of information. The
Cochrane Collaboration was founded in 1993 and named after
2

Lisa A. Bero & Drummond Rennie, The Cochrane Collaboration:
Preparing, Maintaining, and Disseminating Systematic Reviews of the Effects of
Healthcare, 274 JAMA 1935, 1935-38 (1995); Lisa A. Bero & Alejandro R.
Jadad, How Consumers and Policymakers can use Systematic Reviews for
Decision Making, 127 ANN. INTERNAL MED. 37, 37-42 (1997); Deborah J. Cook
et al., Systematic Reviews: Synthesis of Best Evidence for Clinical Decisions,
126 ANN. INTERNAL MED. 376, 376-80 (1997).
3
Cook et al., supra note 2.
4
See infra note 65.
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British epidemiologist, Archie Cochrane. In 1979, Cochrane wrote
that “[i]t is surely a great criticism of our profession that we have
not organized a critical summary, by specialty or subspecialty,
adapted periodically, of all relevant randomized controlled trials.”5
The long term goal of the Cochrane Collaboration is to develop
these critical summaries of all trials of all healthcare interventions.
The Cochrane Collaboration is an international non-profit
organization that aims to help people make well-informed
decisions about healthcare by preparing, maintaining and
promoting the accessibility of systematic reviews of the effects of
healthcare interventions. It produces and disseminates systematic
reviews of healthcare interventions and promotes the search for
evidence in the form of clinical trials and other studies of
interventions.6 The major product of the Collaboration is the
Cochrane Database of Systematic Reviews, which is published
quarterly as part of the Cochrane Library.7
5

Archie L. Cochrane, 1931-1971: A Critical Review, with Particular
Reference to the Medical Profession, in LONDON: OFFICE OF HEALTH
ECONOMICS, MEDICINES FOR THE YEAR 2000 1-11 (1979).
6
The Cochrane Collaboration Home Page, http://www.cochrane.org (last
visited May 9, 2006).
7
See infra note 65. The Cochrane logo (Figure 1) is a meta-analysis of 7
randomized controlled trials comparing a short, inexpensive course of a
corticosteroid to placebo in women with premature labor. The data for these
trials are shown as “odds ratios,” meaning the odds of patients in the treated
group having the outcome divided by the odds of the patients in the placebo
group having the outcome. An odds ratio is just one way of representing the
point estimate, or result, of a trial. Each horizontal line represents the results of
one trial; the middle of the line is the point estimate for the odds ratio and the
ends of the line represent the variability around this estimate. The shorter the
line, the larger the trial and the more certain the result. In the case of the
Cochrane logo, an odds ratio of less than one will show a favorable effect of the
treatment because this would mean that the odds of a woman in the
corticosteroid group having a baby die from complications of premature labor
would be less than the odds of a woman in the placebo group. As seen in the
figure, the seven trials all yield slightly different point estimates or odds ratios.
The diamond represents the statistical combination of the results of all seven
trials. The vertical line indicates an odds ratio of one, or the position at which
there would be no difference in outcome between the treated and control groups.
If a horizontal line touches the vertical line, it means that that particular trial
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The validity of a systematic review depends on the extent to
which the methods of the review reduce random error and
systematic bias. Systematic reviews reduce bias because they are
conducted according to strictly defined methods. A good
systematic review contains a focused question, an explicit and
comprehensive search strategy, explicit inclusion and exclusion
criteria that are uniformly applied, a rigorous critical appraisal of
each identified study and, if appropriate, a quantitative summary of
the evidence.8
Part I of this paper discusses the importance of systematic
reviews and meta-analyses for evidence-based medicine by
highlighting the benefits systematic reviews provide researchers
and funders over reliance on individual studies. Part II offers a
primer on how to evaluate a systematic review to best eliminate
bias in the review and provides some general guidelines for each
step in the optimal review process.
I.

THE IMPORTANCE OF SYSTEMATIC REVIEWS

Systematic reviews are a way of dealing with the massive
information overload that is typical of clinical medicine.
Systematic reviews are an efficient scientific technique for
gathering, critiquing and summarizing large amounts of
information. A systematic review allows the reader to see when
scientific findings are consistent. When studies that are done in
slightly different ways or in slightly different populations reach the
same answer, we can assume that the results may be generalizable
to a wider population. On the other hand, systematic reviews allow
for the exploration of inconsistencies and conflicts in the results of
individual studies. By presenting the same information on all
studies in the systematic reviews, the review allows the reader to
determine whether divergent results might be due to differences in
found no clear difference between the treatments. The position of the diamond
to the left of the vertical line indicates that the treatment studied is beneficial.
The logo demonstrates that corticosteroid therapy for women in premature labor
is an effective intervention.
8
Cynthia D. Mulrow, The Medical Review Article: State of the Science,
106 ANN. INTERNAL MED. 485 (1987).
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the methods of the original studies, differences in the experimental
intervention tested, or variability in the characteristics of the
populations tested.
Increasing the power, or sample size, of a study reduces
random error. The larger the study, the more likely that the results
will be distributed around the true effect. In smaller studies, due to
chance and random error, the results are less likely to represent the
true effect. Meta-analysis increases the power of a study because it
combines the results of a number of small studies into one study
with a larger sample size. Thus, meta-analysis increases the
precision of an estimate of an effect by decreasing the variability
around the estimate as the sample size increases.
A common myth about meta-analysis is that if enough studies
are combined, the results will always be statistically significant, or
demonstrate an effect. This is not the case, however, as illustrated
by a meta-analysis of randomized, controlled trials of prophylactic
lidocaine for acute myocardial infarction.9 In this meta-analysis,
the results of eight small randomized controlled trials of lidocaine
were combined. When the studies were statistically combined into
a meta-analysis of almost 9,000 patients, the summary estimate
remained statistically non-significant, thus showing there was no
effect of lidocaine.
Another valuable contribution of systematic reviews is that
they can help set research agendas (and avoid embarrassment of
researchers) by identifying what questions have been answered, as
well as gaps in understanding. This contribution is best illustrated
with the technique of cumulative meta-analysis, which means that
each study in the meta-analysis is added in consecutively.10 Figure
2,11 represents the results of a cumulative meta-analysis of
randomized controlled trials examining the effect on mortality of

9

Elliott M. Antman et al., A Comparison of Results of Meta-analyses of
Randomized Control Trials and Recommendations of Clinical Experts:
Treatments for Myocardial Infarction, 268 JAMA 240, 242-44 (1992).
10
Joeseph Lau et al., Cumulative Meta-analysis of Clinical Trials Builds
Evidence for Exemplary Medical Care, 48 J. CLIN. EPIDEMIOL. 45, 45-47, 59-60
(1995).
11
See infra note 66.
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thrombolytic therapy following an acute myocardial infarction.12
As shown in the figure, after the enrollment of approximately
6,000 patients in 27 trials over a 20 year period, it was clear that
treatment with thrombolytic therapy reduced mortality. As more
patients were enrolled in more trials, the odds ratio did not change
much, although the variability around the odds ratio decreased as
the sample size of the cumulative meta-analysis increased. Thus,
approximately 42,000 people participated in 43 more trials that
were not needed to determine if a thrombolytic therapy effectively
reduces mortality after a myocardial infarction. Meta-analysis is a
valuable tool for helping researchers and funders decide when
more research is needed to answer a clinical question.
If a good systematic review is available, should one rely on the
results of an individual study to answer a clinical question? The
answer is no. Systematic reviews and meta-analyses have become
the gold standard for evidence-based medicine. Evidence-based
medicine emphasizes the examination of evidence from clinical
research over intuition, unsystematic clinical observations, and
pathophysiological rationale for clinical decision making.13
Because systematic reviews and meta-analyses of randomized
controlled trials are designed to reduce bias and generalize results
across patients, they are considered to be the top of the “hierarchy
of evidence” for evidence-based medicine.14 Conclusions drawn
from a single randomized controlled trial are generally considered
weaker because they are based on smaller sample size and do not
generalize across different patients.15 The remainder of this paper
will present some general guidelines for evaluating the validity of
12

Antman, supra note 9, at 240-48. Joseph Lau et al., Cumulative Metaanalysis of Therapeutic Trials for Myocardial Infarction, 327 NEW ENG. J. MED.
248, 251 (1992).
13
David L. Sackett & W.M. Rosenberg, The Need for Evidence-based
Medicine, 88 J. ROYAL SOC’Y MED. 620, 620-24 (1995); David L. Sackett,
Evidence-based Medicine, 21 SEMINARS IN PERINATOLOGY 3, 3-5 (1997).
14
Gordon H. Guyatt et al., Users’ Guides to the Medical Literature: IX. A
Method for Grading Healthcare Recommendations, 274 JAMA 1800 (1995);
Cook et al., supra note 2.
15
Joseph C. Cappelleri et al., Large Trials vs. Meta-analysis of Smaller
Trials: How Do Their Results Compare?, 276 JAMA 1332, 1332-38 (1996).
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systematic reviews.
II. EVALUATING SYSTEMATIC REVIEWS
There are many possible sources of bias in reviews, including
the framing of the research question, the selection of studies to be
included, the extraction of data from and critical appraisal of the
included studies, and the analysis. It is sometimes difficult to
detect the source of bias. For example, reviews of studies of
adverse effects related to exposure to secondhand smoke are more
likely to conclude that secondhand smoke is not harmful when the
authors of the reviews are affiliated with the tobacco industry,
regardless of the methodological quality of the review, whether it
was published in a peer-reviewed journal, or other factors.16
One way to avoid bias in a review is to develop a protocol for
the review before commencement and adhere to the protocol
regardless of the results of the review.17 A reader of the review can
then determine whether the authors conducted it according to the
systematic methods proposed. When the reviews are completed,
the readers can be assured that the authors adhered to the methods
of the protocol and did not change the methods after they started
the review. Adherence to a strict protocol can sometimes result in
reviews where no studies that meet the criteria for the review can
be found. However, as mentioned above, these reviews are still
useful for identifying gaps in the research literature.
A good protocol (and completed review) should contain the
following sections: 1) an objective or research question, 2) criteria
for selecting studies for the review, 3) a search strategy for studies,
4) methods for assessing the validity of included studies, 5)
methods for selecting studies for the review, 6) methods for
collecting data from the studies, and 7) an analysis plan.

16

Deborah E. Barnes & Lisa A. Bero, Why Review Articles on the Health
Effects of Passive Smoking Reach Different Conclusions, 279 JAMA 1566,
1566-70 (1998).
17
The Cochrane Library publishes protocols of reviews.
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1. Objectives

Every systematic review should contain a precise statement of
the primary objective or research question. The objective should
include a description of the population to be tested, the
intervention or exposure to be tested, the treatment for the
comparison group, and the outcome.18 In other words, “What is
being tested to change what outcome in whom?”19
Any prior hypotheses and comparison groups should be stated.
This includes pre-specified subgroup analysis. For example, one
might hypothesize that a drug will reduce hypertension only in
non-obese patients. Thus, the review should contain an objective
stating that data from obese patients will be analyzed separately
from data from non-obese patients. Specifying subgroup analysis
after data collection for the review has already begun can be a
“fishing expedition” or “data dredging” for statistically significant
results and is not appropriate.
2. Criteria for Selection of Studies for the Review
The biased citation of studies in a review can be a major source
of error in the results of the review.20 Authors of reviews can
influence their conclusions by citing only studies that support their
preconceived, desired outcome. The clearly stated objective of the
review determines the criteria used to select studies for inclusion in
18

Andrew D. Oxman et al., Users’ Guides to the Medical Literature: VI.
How to Use an Overview, 272 JAMA 1367, 1367-71 (1994).
19
Some examples of clear objectives are:
• Do corticosteroids, compared to no treatment, prevent pre-term labor in
pregnant women?
• Does prophylactic lidocaine, compared to placebo, prevent acute
myocardial infarction in patients who have already had a myocardial
infarction?
• Do calcium channel blockers lower blood pressure in patients with
hypertension compared to placebo? A related question with a different
outcome of interest would be, “Do calcium channel blockers reduce
mortality in patients with hypertension compared to placebo?”
20
Paul F. Neihouse & Susan C. Priske, Quotation Accuracy in Review
Articles, 23 DICP 594, 594-96 (1989).
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the review. The eligibility criteria should include a description of
1) the participants in the studies (e.g., children, men or women
with recent heart attacks), 2) the interventions or exposures (e.g., a
drug, chemical exposure), 3) the outcome measures (e.g.,
mortality, heart attack), and 4) the study design (e.g., randomized
controlled trial, observational study). As mentioned above,
systematic reviews of randomized controlled trials are considered
one of the most rigorous types of clinical evidence. In a
randomized controlled trial, the only difference between the two
groups being compared is the experimental intervention. Thus,
systematic reviews, particularly those examining the effects of
therapeutic interventions, may include only randomized controlled
trials.
The types of study designs to be included in a review will vary
with the research objective. For example, the effects of
environmental toxins are not typically examined using randomized
controlled trials. Thus, a systematic review of the effects of a
potential environmental hazard will include studies of
observational designs, such as cohort or case control studies.21
Even qualitative studies, such as focus groups or interview studies,
can be combined using systematic review methods. For example, a
review of qualitative studies on barriers to childhood vaccination
identified several consistent areas that are obstacles to children
receiving immunizations.22
3. Search Strategy for Identification of Studies
After the inclusion criteria for studies are clearly specified, a
comprehensive search strategy must be developed.23 The search
should be as comprehensive as possible. The review should specify
21

See Barnes & Bero, supra note 16.
Edward Mills et al., Systematic Review of Qualitative Studies Exploring
Parental Beliefs and Attitudes Towards Childhood Vaccination Identifies
Common Barriers to Vaccination, 58 J. CLIN. EPIDEMIOL. 1081, 1081-88 (2005).
23
Carl Counsell & Hazel Fraser, Identifying Relevant Studies for
Systematic Reviews, 310 BMJ 126 (1995); Maureen O. Meade & W. Scott
Richardson, Selecting and Appraising Studies for a Systematic Review, 127
ANN. INTERNAL MED. 531, 531-37 (1997).
22
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the exact dates of the search and whether there were any language
restrictions.
Unfortunately, a print review article is out of date as soon as it
is published. Thus, regular updating of reviews, such as those in
the Cochrane Library, is essential for ensuring the accuracy of the
information. Although the end date of a search for studies should
be as recent as possible (and regularly updated), the start date of
the search should be appropriate to the question. For example, if no
trials of a particular drug were conducted before 1985, it is not
necessary to extend the search prior to that date. In some cases, the
circumstances under which research is conducted may change. For
example, the definition of the AIDS diagnosis was refined during
the late 1980’s. Trials of HIV/AIDS therapies conducted in the
early 1980’s may have included different populations than those
conducted in the 1990’s. Thus, reviews of these therapies should
clearly specify the rationale for the search dates.
Many systematic reviewers restrict their searches to English
language-only studies. However, this is primarily for the sake of
convenience and can introduce a number of limitations. The
methodological quality of clinical trials does not vary by language
of the publication, so quality concerns are not a good justification
for language restrictions.24 Furthermore, the results of systematic
reviews can change completely when the review includes only
English language studies or studies in any language. Gregoire
found that in at least one out of 36 consecutive meta-analyses the
exclusion of papers for language reasons produced results different
from those which would have been obtained if this exclusion
criteria had not been used.25 As long as a study meets the inclusion
criteria for the review, it should be included regardless of the
language of its publication.
24

D. Moher et al., Completeness of Reporting of Trials Published in
Languages Other Than English: Implications for Conduct and Reporting of
Systematic Reviews, 347 LANCET 363, 363-36 (1996); Matthias Egger et al.,
Language Bias in Randomised Controlled Trials Published in English and
German, 350 LANCET 326, 326-29 (1997).
25
G. Gregoire et al., Selecting the Language of the Publications Included in
a Meta-Analysis: Is There a Tower of Babel Bias?, 48 J. CLIN EPIDEMIOL. 159,
159-63 (1995).
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Electronic databases of research articles are a good starting
place to search for studies that meet the inclusion criteria for a
systematic review. MEDLINE or PubMed (produced for free by
the National Library of Medicine) is the most commonly used
database. However, a PubMed search identifies only about 50% of
randomized controlled trials published in journals that are indexed
by MEDLINE. Comparison of a MEDLINE search with a “gold
standard” search based on manual, page-by-page searching of
journals for randomized controlled trials found that MEDLINE
was not good at detecting trials.26 The poor performance of
MEDLINE is due to the improper indexing of randomized
controlled trials, as well as the inappropriate use of search terms.27
Clearly, searching MEDLINE alone is inadequate for identifying
randomized controlled trials. Supplementing the MEDLINE search
with other electronic database searches can be useful. EMBASE
indexes more than 100 journals that are not indexed in MEDLINE,
including many non-English language journals, and LILACS is the
largest electronic database of Spanish-language medical journals.
Specialty electronic databases can also be useful, depending on the
topic of the research questions. CINAHL, PsychLit, CancerLit and
BIOSIS are examples of specialty databases.
As all electronic databases have limitations, a good review
should employ additional methods for identifying studies that meet
the inclusion criteria. Checking the reference lists of studies that
are identified in the electronic searches often identifies additional
studies. In addition, citation databases, such as Web of Science,
can locate additional studies. These databases identify articles that
cite the studies that were identified in the initial electronic search.
Lastly, hand searching or the manual, page-by-page searching of
journals for randomized, controlled trials is the gold standard for
identifying studies. The Cochrane Collaboration has led an effort
in hand searching journals to identify trials and these trials are
indexed in the Cochrane Library.28
26

Kay Dickersin et al., Identifying Relevant Studies for Systematic Reviews,
309 BMJ 1286, 1286-91 (1994).
27
Id.
28
Id.
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Systematic reviewing and meta-analysis proceeds under the
assumption that a complete and representative sample of relevant
studies is available for analysis.29 However, because access to
relevant studies is frequently limited to published studies,
systematic reviews and meta-analyses are particularly vulnerable
to biases that may affect the publication of studies. The majority of
methodologists and journal editors now believe that unpublished
data should be included in systematic reviews, suggesting
widespread belief that important data remain unpublished.30
The problem of publication bias, the tendency for studies
showing statistically significant results to be published and
published more quickly than studies with statistically nonsignificant results, poses a serious challenge to identifying studies
for systematic reviews. First identified in 1959,31 publication bias
raises the concern that statistically significant study results may
dominate the research record, thus reducing the range of evidence
on which systematic reviews and meta-analyses are based.32 A
recent study modeling the probability of finding statistically
significant findings that are not correct has concluded that “most
published research findings are false.”33 Most studies also show
29

Jerome M. Stern & R. John Simes, Publication Bias: Evidence of
Delayed Publication in a Cohort Study of Clinical Research Projects, 315 BMJ
640, 640-45 (1997).
30
Debra J. Cook et al., Should Unpublished Data Be Included in Metaanalyses? Current Convictions and Controversies, 269 JAMA 2749, 2749-53
(1993).
31
Theodore D. Sterling, Publication Decisions and Their Possible Effects
on Inferences Drawn from Tests of Significance - or Vice Versa, 54 J AM. STAT.
ASS’N 30, 30-34 (1959).
32
Kay Dickersin et al., Publication Bias and Clinical Trials, 8 CONTROL
CLININCAL TRIALS 343, 343-53 (1987); Phillipa J. Easterbrook et al.,
Publication Bias in Clinical Research, 337 LANCET 867, 867-72 (1991);
Anastasia L. Misakian & Lisa A. Bero, Publication Bias and Research on
Passive Smoking: Comparison of Published and Unpublished Studies, 280 JAMA
250, 250-53 (1998).
33
John P.A. Ioannidis, Why Most Published Research Findings are False,
MEDICINE
101,
101-06
(2005),
available
at
2
PLOS
http://medicine.plosjournals.org/archive/1549-1676/2/8/pdf/10.1371_journal.
pmed.0020124-S.pdf.
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that not only statistical significance but a large sample size is also
associated with publication, so that small, statistically nonsignificant studies are rarely published. Thus, the results of
systematic reviews and meta-analyses can be skewed in favor of
new treatments showing positive initial results.34 Publication bias
poses a particular threat to the reliability and validity of systematic
reviews and meta-analysis by leading to spuriously large treatment
effects in early meta-analyses of the available evidence.35
Thus, authors of systematic reviews must attempt to identify
unpublished and ongoing studies through a variety of methods.
Searching the abstracts of conference proceedings, of which only
about 50% are published as full journal articles,36 is one
mechanism for identifying unpublished studies. Personal
communication with investigators who are active in the field is
another method. Searching clinical trial registries is one of the
most promising methods for identifying unpublished data.
Registration of clinical trials is one method that has been
proposed to reduce publication bias.37 The exposure of notable
cases of data suppression from clinical trials prompted the
International Committee of Medical Journal Editors and its 11
member journals to require, as a condition of consideration for
publication, registration of clinical trials in a public trials
registry.38 Although extensive debate about the specific content of
trial registries continues, the increasing availability of such
registers will make it easier to identify unpublished studies for
systematic reviews.

34

John P.A. Ioannidis et al., Issues in Comparisons Between Meta-analyses
and Large Trials, 279 JAMA 1089, 1089-93 (1998).
35
Id.
36
Roberta W. Scherer et al., Full Publication of Results Initially Presented
in Abstracts: A Meta-Analysis, 272 JAMA 158, 158-62 (1994).
37
Robert John Simes, Publication Bias: The Case for an International
Registry of Clinical Trials, 4 J. CLINICAL ONCOLOGY 1529, 1529-41 (1986).
38
Kay Dickersin & Yuan I. Min, Publication Bias: The Problem that
Won’t Go Away, 703 ANN. N.Y. ACAD. SCI. 135, 146-48 (1993); Catherine D.
DeAngelis et al., Clinical Trial Registration: A Statement from the International
Committee of Medical Journal Editors, 292 JAMA 1363, 1363-64 (2004).
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4. Assessment of Methods Used to Reduce Bias in the Selected
Studies

Bias is the combination of various design, data, analysis and
presentation factors that tend to produce statistically significant
research results that are not true.39 Various factors can lead to
statistically significant outcomes in randomized controlled trials of
drug efficacy, including framing of the research question, design
and analysis of the study, and conduct of the study.40 Reporting (or
not) of the full results or selective reporting of outcomes can also
contribute to the problem of publication bias.41 One criticism of
meta-analyses and systematic reviews is: “Garbage in, garbage
out.” This means that if poorly designed and executed studies that
fail to minimize bias are included in a systematic review, the
results of the review will not be valid. Therefore, it is essential that
the studies that are included in a systematic review are evaluated
for their methodological quality—the methods used to reduce bias.
The tools used to evaluate methodological quality should be
specific to the study design being evaluated. As most evaluation
tools have been developed to assess the quality of randomized
controlled trials, the following section will focus on the evaluation
of trials. However, instruments for assessing the methods of
observational and qualitative studies are also available.42
5. How Do We Measure Quality?
Dozens of instruments for assessing the methodological quality
39

Ioannidis, supra note 33.
Cochrane Collaboration, supra note 6.
41
Id.; Richard Smith, Medical Journals are an Extension of the Marketing
Arm of Pharmaceutical Companies, 2 PLoS Med. 364, 364-66 (2005), available
at
http://medicine.plosjournals.org/archive/1549-1676/2/5/pdf/10.1371_
journal.pmed.0020138-L.pdf.
42
Andrew D. Oxman & David L. Sackett, Users’ Guides to the Medical
Literature: I. How to Get Started. The Evidence-Based Medicine Working
Group, 270 J. AM. MED. ASS’N 2093, 2093-95 (1993); Mildred K. Cho & Lisa
A. Bero, Instruments for Assessing the Quality of Drug Studies Published in the
Medical Literature, 272 J. AM. MED. ASS’N 101, 101-04 (1994).
40
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of randomized controlled trials exist,43 including some frequently
used instruments that contain from 3 to 22 items.44 In 1995, Moher
examined 25 published scales and 9 checklists for measuring the
methodological quality of randomized controlled trials.45 Most of
these instruments calculate a quality “score” for the randomized
controlled trial.
There are several problems with all of these quality assessment
instruments. First, reliability and validity have not been measured
for most of them. A reliability measurement would provide
information on how often multiple coders, using the instruments
independently, would derive the same score. A validity measure
would provide information on whether the items assessed in the
instrument are truly evaluating methods that reduce bias.
Second, most methodological quality assessment instruments
combine the evaluation of reporting and actual study design. If two
studies that are designed in an identical way are published in
different journals, one may be reported more completely than the
other. The more completely reported study would have a better
quality score, although it is not truly a better designed study. In
order to reduce the problem of variability in reporting, systematic
reviewers often correspond with the authors of the studies to obtain
information that is not in the study report. In addition, in recent
years, many journals have developed reporting standards and have
strengthened their policies regarding reporting of randomized
controlled trials.46
A third problem with the quality assessment instruments is that
there is little empirical evidence to support differential weighting
of the individual components of the quality scores. Individual
characteristics of randomized controlled trials that are associated
43

See D. Moher et al., Assessing the Quality of Randomized Controlled
Trials: An Annotated Bibliography of Scales and Checklists, 16 CONTROLLED
CLINICAL TRIALS 62, 62-73 (1995); See also Moher, supra note 24.
44
Thomas C. Chalmers et al., A Method for Assessing the Quality of a
Randomized Control Trial, 2 CONTROLLED CLIN. TRIALS 31, 31-49 (1981); Cho
& Bero, supra note 42.
45
Moher, supra note 43.
46
Colin Begg et al., Improving the Quality of Reporting of Randomized
Controlled Trials: The CONSORT Statement, 276 JAMA 637, 637-39 (1996).
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with bias have been identified in studies evaluating a variety of
randomized controlled trials. These characteristics include
inadequate randomization47 and concealment of allocation.48
Concealment of allocation means that investigators, at the
beginning of the study and before any patients are assigned to
treatment, are unaware of the group to which a patient will be
randomly assigned. Other characteristics of randomized controlled
trials that are associated with bias are inadequate double blinding,49
insufficient sample size,50 inappropriate choice of drugs to be
compared,51 and inappropriate choice of statistical analysis.52 For
47

Thomas C. Chalmers et al., Controlled Studies in Clinical Cancer
Research, 287 NEW ENG. J. MED. 75, 75-78 (1972); Graham A. Colditz et al.,
How Study Design Affects Outcomes in Comparisons of Therapy, 8 STAT. MED.
441 (1989).
48
Kenneth F. Schulz, Subverting Randomization in Controlled Trials, 274
JAMA 1456, 1456-58 (1995) [hereinafter Schulz, Subverting Randomization];
Kenneth F. Schulz et al., Empirical evidence of bias. Dimensions of
Methodological Quality Associated With Estimates of Treatment Effects in
Controlled Trials, 273 JAMA 408, 408-12 (1995) [hereinafter Schulz, Empirical
Evidence].
49
Colditz, supra note 47; Schulz, Empirical Evidence, supra note 48.
50
John P. Ioannidis, Effect of the Statistical Significance of Results on the
Time to Completion and Publication of Randomized Efficacy Trials, 279 JAMA
281, 281-86 (1998); Misakian & Bero, supra note 32; Bodil Als-Nielsen et al.,
Association of Funding and Conclusions in Randomized Drug Trials: A
Reflection of Treatment Effect or Adverse Events?, 290 JAMA 921, 921-28
(2003); John P. Ioannidis et al., Randomised Trials Comparing Chemotherapy
Regimens for Advanced Non-small Cell Lung Cancer: Biases and Evolution
Over Time, 39 EUR. J. CANCER 2278, 2778-87 (2003); Bodil Als-Nielsen et al.,
Are Trial Size and Quality Associated with Treatment Effects in Randomised
Trials?, 12TH ANNUAL COCHRANE COLLOQUIUM (2004).
51
P.A. Rochon, et al., A Study of Manufacturer-Supported Trials of
Nonsteroidal Anti-inflammatory Drugs in the Treatment of Arthritis, 154
ARCHIVES INTERNAL MED. 157, 157-63 (1994); Helle Krogh Johansen & Peter
C. Gotzsche, Problems in the Design and Reporting of Trials of Antifungal
Agents Encountered During Meta-analysis, 282 JAMA 1752, 1752-59 (1999);
Benjamin Djulbegovic et al., The Uncertainty Principle and Industry-Sponsored
Research, 356 THE LANCET 635, 635-38 (2000); Daniel Safer, Design and
Reporting
Modifications
in
Industry-Sponsored
Comparative
Psychopharmacology Trials, 190 J. OF NERVOUS AND MENTAL DISEASE 583,
583-92 (2002).
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example, Schulz and colleagues found that estimates of treatment
effects were exaggerated by 41% for inadequately concealed trials
and by 17% for trials with inadequate double blinding.53
Most quality assessment instruments assign points for using
appropriate methods for each component of the randomized
controlled trial, and sum these points into the quality score. Recent
research suggests that these scores are not valid measures of
methodological quality. Juni and colleagues determined that the
use of different quality assessment scales using summary scores
resulted in different conclusions of meta-analytic studies and
proposed that specific components of methodological quality (e.g.,
concealment of allocation, blinding) should be individually
assessed.54 Therefore, the use of quality scores to rate the studies
included in a meta-analysis should be viewed with caution.
Reporting each included study’s performance on the individual
components of the quality score is more informative.
Some systematic reviewers also report additional
characteristics of included studies that are not strictly measures of
methodological quality. For example, peer-reviewed journal
articles are less likely to have statistically significant outcomes
than non-peer-reviewed journal articles.55 In addition, a large body
of evidence suggests that industry sponsorship of research is also
associated with statistically significant results that are favorable to
the sponsor. Two recent systematic reviews identified 19 studies
examining the association of industry sponsorship and research
outcomes.56 The magnitude of this observed association is variable.
52

Oscar H. Brook et al., Effects of Coaching by Community Pharmacists on
Psychological Symptoms of Antidepressant Users: A Randomised Controlled
Trial, 13 EUR. NEUROPSYCHOPHARMACOLOGY 347, 347-54 (2003); Jorge
Gomez Cerezo et al., Outcome trials of COX-2 Selective Inhibitors: Global
Safety Evaluation Does Not Promise Benefits, 59 EUR. J. CLINICAL
PHARMACOLOGY 169, 169-75 (2003).
53
Schulz, Subverting Randomization, supra note 48.
54
Peter Juni et al., The Hazards of Scoring the Quality of Clinical Trials
for Meta-analysis, 282 JAMA 1054, 1054-60 (1999).
55
Mildred K. Cho & Lisa A. Bero, The Quality of Drug Studies Published
in Symposium Proceedings, 124 ANN. INTERN. MED. 485, 485-89 (1996).
56
Justin E. Bekelman et al., Scope and Impact of Financial Conflicts of
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For example, review articles on the health effects of secondhand
smoke exposure that are written by tobacco industry-supported
authors are about 90 times more likely to conclude that secondhand
smoke is not harmful than those that are written by authors not
affiliated with the tobacco industry.57 Pharmaceutical industrysponsored drug studies are about 4 times more likely to have
conclusions that favor the sponsor than those that are funded by
non-pharmaceutical sponsors.58 Financial ties of investigators to
their sponsors (e.g., stock ownership, consulting income,
honoraria) are also associated with favorable research outcomes for
the sponsor.59
In summary, a systematic reviewer should use common sense
measures to assess the methods of studies that are included in the
review. The components that are assessed for each included study
should focus on the key features of the study, should be
empirically verified to influence outcome, and should be reported
individually. Systematic reviewers must keep in mind that the
evaluation of included studies could indicate that all the studies are
flawed. In this case, no conclusions should be drawn from the
studies included in the review.
6. Methods for Selecting Studies for the Review, Extracting
Data, and Appraisal of Studies
Bias can be introduced during the selection of studies for
inclusion in the review, as well as during the extraction and
appraisal of data from the studies. Rigorous systematic reviewers
often use two coders to independently select the studies from the
list generated by the comprehensive search. The study selection
should be done according to an explicit, written list of inclusion
criteria. The coders should keep a written record of which criteria
are met by each included study. The systematic review should also
Interest in Biomedical Research: A Systematic Review, 289 JAMA 454, 454-65
(2003); Joel Lexchin et al., Pharmaceutical Industry Sponsorship and Research
Outcome and Quality: Systematic Review, 326 BMJ 1167, 1167-70 (2003).
57
Barnes & Bero, supra note 16, at 1566-70.
58
Lexchin, supra note 6.
59
Id.
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include a table of excluded studies listing the reasons why each
study was excluded. Such a table is useful for determining if bias
was introduced into the study selection process.
Two coders should also independently extract data from each
included article and perform the quality assessment. Coders should
be trained to use a data extraction form and be provided with a
comprehensive set of instructions. Studies are sometimes assessed
in random order using a computer random number generator in
order to avoid the “training” effect that occurs as coders become
more familiar with the data extraction instrument.
Systematic reviews sometimes report the inter-rater agreement
among multiple coders. A higher degree of agreement gives the
reader more confidence that the selection and data extraction
process did not introduce bias into the review. Often disagreements
between coders can be resolved by consensus. In these cases, the
consensus is often reported in the review.
Reviewers are sometimes masked or blinded to the authors,
authors’ institutions, or journals in which studies are published.
However, complete blinding is difficult to achieve. Furthermore,
there is no evidence that the masking of the data coders influences
their selection or quality ratings.60 Therefore, it is less common for
more recent systematic reviews to mask reviewers to the identity or
sources of the studies.
In summary, a systematic review should include a description
of how the data collection was done and whether it is complete.
The review should report that pre-tested, standardized data
collection forms were used by multiple coders working
independently. The methods to resolve disagreements among the
coders should be described. In addition, efforts to obtain
information that was missing from the original study reports
should be described. For each study included in the review, data
should be reported on: methods (including study design, individual
60

A.R. Jadad et al., Assessing the Quality of Reports of Randomized
Clinical Trials: Is Blinding Necessary?, 17 CONTROLLED CLINICAL TRIALS 1, 112 (1996); J.A. Berlin, Does Blinding of Readers Affect the results of MetaAnalyses? University of Pennsylvania Meta-analysis Blinding Study Group, 350
LANCET 185, 185-186 (1997); M. Clarke et al., Individual Patient Data MetaAnalysis in Cancer, 77 BRITISH J. OF CANCER 2036, 2036-44 (1998).
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quality assessment components), participants, interventions,
outcomes, and results (recorded in natural units and converted to a
common effect size when possible).
7. Data Synthesis—A Meta-analysis or Not?
The last step in conducting a systematic review is to decide
whether the data resulting from the search, data extraction and
critical appraisal should be summarized quantitatively into a metaanalysis. Data from the included studies should be quantitatively
combined into a point estimate only if the participants,
interventions, and outcomes are sufficiently similar. Although
there are statistical techniques available to assess the heterogeneity
of studies, deciding whether to combine results is largely a
judgment call.61 Data from individual studies should never be
statistically combined if no studies of good methodological quality
exist or if a very broad question is being addressed. Thus, it is
acceptable to combine oranges and oranges or apples and apples.
Although it is not acceptable to statistically combine apples and
oranges, it is acceptable to do a systematic review of apples and
oranges as long as one is interested in fruit. For example, if a
reviewer is interested in the efficacy of continuing medical
education (CME) to change physician behavior, she will gather
studies that have tested a variety of educational methods, such as
lecture, problem-based small groups, or online courses. The
reviewer could include all of these studies in a systematic review
in order to get an overview of how CME is conducted. However,
she should only statistically combine studies that tested the same
intervention, i.e., lectures or small groups.
“Vote counting” is not a valid method for summarizing the
results of a systematic review. For example, if a review includes 11
studies, one might conclude that the intervention is effective if 7
studies found a statistically significant effect of the intervention
and 4 did not. This vote count, however, negates many of the
strengths of the systematic review technique, such as giving more
61

JOSEPH L. FLEISS ET AL., STATISTICAL METHODS
PROPORTIONS 161-165 (John Wiley & Sons Inc. 3d ed. 2003).
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weight to studies of better methodological rigor. If the most poorly
designed studies are those that show the significant effect, the
conclusion that the intervention works may be erroneous. Thus,
statistical combination of data from similar studies allows for the
weighting of the studies according to their design characteristics,
sample size, or other features that might affect outcome. If a metaanalysis is to be conducted, reviewers need to decide how the
effect of the intervention examined in each study will be
summarized. A discussion of the appropriateness of different
summary statistics for a meta-analysis is beyond the scope of this
paper.62 However, the statistical methods used to combine data for
meta-analyses do not differ in principal from those used in primary
research. Parametric, non-parametric, regression and Bayesian
techniques can be used.63 The statistic chosen should be
appropriate to the type of data analyzed and the reasons for
choosing the statistic should be transparent. For example,
dichotomous data, such as mortality, may be summarized as an
odds ratio, relative risk, absolute risk difference, and number
needed to treat.64 Continuous data, such as blood glucose or blood
pressure, can be combined directly if measured on the same scale,
or converted to a common metric if measured on different scales.
Although different statistical methods are used to combine data
from observational studies, the principles of combining similar
studies and exploring reasons for heterogeneity among studies are
the same.65
62

See Joseph Lau et al., Quantitative Synthesis in Systematic Reviews, 127
SYSTEMATIC REV. SERIES 91, 91-101, (Cynthia Mulrow, MD, MSc & Deborah
Cook MD, MSc eds., 1997).
63
J. L. Fleiss, The Statistical Basis of Meta-Analysis, 2 STAT. METHODS
MED. RES. 121, 121-45 (1993); I. Olkin, Statistical and Theoretical
Considerations in Meta-Analysis, 48 J. CLIN. EPIDEMIOL. 133, 147 (1995); T.C.
Smith et al., Bayesian Approaches To Random-Effects Meta-Analysis: A
Comparative Study, 14 STAT. MED. 2685, 2685-99 (1995).
64
J.C. Sinclair & M. B. Bracken, Clinically Useful Measures of Effect in
Binary Analyses of Randomized Trials, 47 J. CLIN. EPIDEMIOL. 881, 881-89
(1994).
65
S. Greenland & M. P. Longnecker , Methods for Trend Estimation from
Summarized Dose-response Data, with Applications to Meta-analysis, 135 AM J.
EPIDEMIOL. 1301, 1301-09 (1992); W. Dumouchel, Meta-analysis for Dose-
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As described in the section on identifying studies, a good
systematic reviewer will attempt to control for publication bias by
conducting a comprehensive search for ongoing and unpublished
studies. However, most meta-analyses also contain a statistical
estimate of publication bias.66 These estimates tell the reader of the
review whether publication bias exists among the studies included
in the review and whether imputed results from unpublished
studies might change the result of the review.
H. Sensitivity Analyses
Regardless of the statistical method used to combine data,
sensitivity analyses should be conducted to measure the robustness
of the summary effect. Variation in the characteristics of patients,
interventions and study design features is inevitable across
different types of studies. Therefore, it is important to explore
whether any variation in the outcomes of the studies are due to
these expected differences. A sensitivity analysis determines
whether the summary point estimate is influenced by the
assumptions made in conducting the systematic review. For
example, a sensitivity analysis could be conducted in which the
summary statistic is calculated first using all included studies, then
recalculated after studies with certain characteristics are deleted
from the analysis. If the results of the meta-analysis remain
consistent, one has more confidence in the results of the review
since it is not dependent on specific features of the included
studies. Sensitivity analyses are often conducted by excluding
studies that are of poor methodological quality, unpublished, or did
not meet all of the inclusion criteria. Sensitivity analyses may also
be conducted by reanalyzing data using a range of results from a
Response Models, 14 STAT. MED. 679, 679-85 (1995); S. J. Smith et al., On
Combining Dose-response Data from Epidemiological Studies by Meta-analysis,
14 STAT. MED. 531, 531-44 (1995).
66
Colin B. Begg, Publication Bias, in THE HANDBOOK OF RESEARCH
SYNTHESIS (Harris Cooper and Larry V. Hedges eds. 1994). Parametric tests are
used when data are normally distributed, non-parametric tests are used when
data are not normally distributed, regression techniques take multiple factors
into account, and Bayesian techniques include assessments of prior probabilities.
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trial (due to inconsistencies in reporting or how outcomes were
measured), reanalyzing data using a range of results for missing
data or reanalyzing the data using different statistics.
CONCLUSION
Systematic reviews and meta-analyses are powerful methods
for gathering, critiquing and summarizing medical and scientific
information. Meta-analysis is a quantitative approach to
systematically combining the results of previous studies.
Systematic reviews are combinations of results that adhere to
pre-defined methods, but that may not result in quantitative
combination of the data. The validity of a systematic review
depends on the extent to which the methods of the review reduce
random error and systematic bias. Systematic reviews reduce bias
because they are conducted according to strictly defined methods
that should be pre-specified in a protocol. A good systematic
review contains a focused research question, an explicit and
comprehensive search strategy, explicit inclusion and exclusion
criteria that are uniformly applied by multiple coders, a rigorous
critical appraisal of each identified study and, if appropriate, a
quantitative summary of the evidence.
Figure 167

67

The Cochrane Collaboration Home Page, see supra note 5.
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Figure 268

68

Antman, supra note 9, at 240-48.

7/30/2006 12:34 PM

BERO MACRO CORRECTED 7-30-06.DOC

7/30/2006 12:34 PM

SYSTEMATIC REVIEWS AND META-ANALYSES

Thrombolytic
Therapy
Year

Cumulative 0.5
RCTs

1.0

2.0
Patients

1

12

2

65

1965

3

149

1970

4
7

316
1,793

1960

10
11
15
17
22
1980
1985

1990

P<.01

23
27

5,767
6,125

30
33
43
54
65
67
70

P<.001
P<.00001

Odds Ratio (Log Scale)
Derived fromAntmanet. al., JAMA
1992

2,544
2,651
3,311
3,929
5,452

Favors Treatment

FavoursControl

6,346
6,571
21,059
22,051
47,185
47,531
48,154

593

